Key clinical point: Stereotactic body radiation therapy may increase the efficacy of nivolumab and ipilimumab in metastatic renal cell carcinoma.
Major finding: The objective response rate was 56%, but this did not meet the prespecified threshold for efficacy (70%).
Study details: A single-center, phase 2 trial of 25 patients with metastatic clear-cell renal cell carcinoma.
Disclosures: The trial was funded by KidneyCAN. The presenter disclosed relationships with Bristol-Myers Squibb, which markets nivolumab and ipilimumab, as well as other companies.
Hammers HJ et al. GUCS 2020, Abstract 614.